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Although Saimiri Transforming Protein (STP)-A11, an oncoprotein ofHerpesvirus saimiri, has been known to activate NF-κB signaling pathway,
the detailed mechanism has not been reported yet. We herein report that STP-A11 activates non-canonical NF-κB pathway, resulting in p100
processing to p52. In addition, translocation of p52 protein (NF-κB2) into the nucleus is observed by the expression of STP-A11. STP-A11-mediated
processing of p100 to p52 protein requires proteosome-mediated proteolysis becauseMG132 treatment clearly blocked p52 production in spite of the
expression of STP-A11. Analysis of STP-A11mutants to activate NF-κB2 pathway discloses the requirement of TRAF6-binding site not Src-binding
site for STP-A11-mediated NF-κB2 pathway. Blockage of STP-A11-mediated p52 production using siRNA against p52 enhanced a
chemotherapeutic drug-mediated cell death, suggesting that p52 production induced by the expression of STP-A11 would contribute to cellular
transformation, which results from a resistance to cell death.
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Mammalian cells express five NF-κB members; RelA (p65),
RelB, c-Rel, NF-κB1 (p50) and NF-κB2 (p52), which combine
to form homo- and heterodimers (Ghosh et al., 1998). Both p50
and p52 protein are mature products from proteolytic processing
of the p105 and p100 precursor protein, respectively (Siebenlist
et al., 1994). NF-κB plays crucial roles in the activation of genes
involved in inflammatory responses, apoptosis and cell survival
and proliferation (Barkett and Gilmore, 1999; Ghosh et al.,
1998). Activation of a canonical NF-κB signaling pathway has
well known to be involved in Tumor necrosis factor receptor
(TNFR) and Toll/IL-1 receptor-mediated signaling (Ghosh and⁎ Corresponding author. Fax: +1 82 51 514 2358.
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doi:10.1016/j.virol.2006.09.001Karin, 2002; Karin and Ben-Neriah, 2000). These signals
induce phosphorylation and subsequent degradation of IκB-α,
an inhibitory molecule that resides in the cytoplasm and
prevents entry of p65:p50 NF-κB dimers to the nucleus. Signal-
induced phosphorylation of IκB-α is mediated by the IκB
kinase (IKK) complex, which comprises IKK1 (IKKα), IKK2
(IKKβ) and IKK-γ (Ghosh and Karin, 2002; Karin and Ben-
Neriah, 2000). Extensive studies on the canonical NF-κB
activation has reveled that IKK2 and IKK-γ are essential for
IκB-α phosphorylation whereas IKK1 is largely dispensable
(Hu et al., 1999; Takeda et al., 1999).
Recently, a non-conical NF-κB activation pathway has
been reported. This pathway involves proteosome-mediated
processing of the NF-κB2 precursor p100 to produce a mature
p52 protein, which then engages RelB and the resulting RelB:
p52 complexes are largely free to migrate into the nucleus
Fig. 1. Induction of NF-κB2, (p52) production by expression of STP-A11. (A, B)
HEK 293 cells and Jurkat T cells were transfected with HA-tagged STP-A11
vector using Ca2+-phosphate precipitation method and electroporation, respec-
tively. After 48 h, whole cell lysates were loaded on 10% SDS–PAGE, and then
p52 and STP-A11 were detected by immunoblotting with anti-p100 monoclonal
antibody (cross-reacts to p52) and anti-HA antibody. The equal amount of protein
loaded on each lane was evaluated with anti-β-tubulin antibody.
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2001a, 2001b). B-cell-activating factor (BAFF) receptor, lym-
photoxin (LT) β receptor, CD40 and LPS receptor have been
known to be involved the non-canonical NF-κB activation
(Claudio et al., 2002; Coope et al., 2002; Dejardin et al., 2002;
Mordmuller et al., 2003; Muller and Siebenlist, 2003). The non-
canonical pathway of NF-κB is mediated by IKK1 and the
mitogen-activated protein 3-kinase NIK, which eventually turns
out no requirement of IKK2 or IKK-γ (Xiao et al., 2001a,
2001b). The non-canonical signaling of NF-κB is crucial for the
development of secondary lymphoid organs as seen in LTβ
receptor, NIK, IKK1, RelB and p52 knockout mice (Franzoso et
al., 1998; Futterer et al., 1998; Kang et al., 2002; Luftig et al.,
2004; Shinkura et al., 1999).
Herpesvirus saimiri (HVS), a member of γ-herpesvirus
family, naturally infects squirrel monkeys (Saimiri sciureus)
without any apparent disease but induces rapidly progressive
fulminant lymphomas in marmoset, owl monkeys and other
species of New World primates (Damania et al., 2000; Jung et
al., 1999). Due to the feature, the studies on HVS have been
extensively performed as an alternative animal model for studies
on Epstein–Barr virus (EBV)- or Kaposi's sarcoma-associated
herpesvirus (KSHV)-mediated pathogenic disease of human
(Jung et al., 1999; Jung and Desrosiers, 1991; Jung and
Desrosiers, 1995). HVS can be further subclassified into three
subgroups (subgroups A, B and C) on the basis of the extent of
DNA sequence divergence at the left end of L-DNA. Subgroups
A and C are highly oncogenic and are able to immortalize
common marmoset T lymphocytes (Medveczky et al., 1984).
Thus, the gene products are designated as saimiri transforming
protein (STP-A or -C) and mutational analysis on STP has
demonstrated that STP is not required for viral replication but for
immortalization (Biesinger et al., 1992). Previous study has
reported that STP-A11 or C488 interacts with TRAF2, 3 and 5
molecules, leading to NF-κB activation and cellular survival
(Lee et al., 1999). Our recent study has shown that STP-A11 also
interacts with and activates Stat3, which might contribute
cellular transformation (Chung et al., 2004).
In this study, we demonstrated that STP-A11 induces a non-
canonical NF-κB activation, which results in translocation of
p52 product from processing of p100 into the nucleus. Blockage
of STP-A11-mediated p52 production using siRNA against p52
enhanced a chemotherapeutic drug-mediated cell death, sug-
gesting that p52 production induced by STP-A11 expression
together with a canonical NF-κB pathway would contribute to
cellular transformation, which results from resistance to the
induction of cell death.
Results
Expression of STP-A 11 induces NF-κB2, p52 production
Our recent studies have shown that saimiri transforming
protein (STP)-A and -C of H. saimiri activate NF-κB through
TRAF2 (Lee et al., 1999) and TRAF6 (in preparation),
proposing that the activation of NF-κB is one of the key factors
in STP-mediated oncogenesis. Because it has been reported thatactivation of NF-κB ismediated by not only a canonical pathway
through RelA:p50 dimers but also by a non-canonical pathway
through RelB:p52 complexes (Ghosh and Karin, 2002), we
wonder whether STP-A11 could utilize a non-canonical
pathway of NF-κB through RelB:p52 dimers. To examine
whether expression of STP-A11, an oncoprotein of HVS,
induces the production of p52 a one of component of NF-κB
from p100 processing, an expression vector of STP-A11 was
transfected into 293 cells.We found that the 293 cells transfected
with STP-A11 produced p52, a processed product of p100 (Fig.
1A). Next, to see if STP-A11 could mediate an alternative
pathway of NF-κB in Jurkat T cells, a biological relevant cell for
HVS, we attempted to express STP-A11 and examined the
induction of p52 (NF-κB2) protein. The expression of STP-A11
induced p52 protein in Jurkat T cells as seen in 293 cells,
whereas transfection of Jurkat T cells with an empty vector did
not (Fig. 1B). On the basis of the result, we propose that
expression of STP-A11 induces the non-canonical pathway of
NF-κB activation, resulting in p52 production from p100, a
precursor protein.
Expression of STP-A11 induces the translocation of p52 into
the nucleus
p100 protein acts as a major IκB protein against RelB in the
cell because p100 protein resides in the cytosol in the complex
with RelB, inhibiting the complex from translocate into the
nucleus. However, activation of cells by stimulants such as LTβ,
LPS and CD40 induces p100 processing (Claudio et al., 2002;
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2003; Muller and Siebenlist, 2003) and its product, p52,
translocates together with RelB into the nucleus. Because we
have shown that STP-A11 induces p52 production from p100
above (Figs. 1A and B), we investigated whether p52 products
from p100 is translocated into the nucleus in the presence of
STP-A11. To do this, HEK 293 cells were transfected with an
expression vector of STP-A11, and then a cytoplasmic and a
nuclear fraction were separated to examine a translocation of
p52 protein to the nuclear fraction. We found that expression
of STP-A11 induces p52 production, leading to translocation
of p52 into the nucleus (Fig. 2A). However, expression of
RelB protein also was induced by STP-A11 expression but
very weakly translocated to the nuclear fraction (data not
shown). The clear separation of cytosol and nuclear fraction
was supported by an observation that β-tubulin protein was
exclusively localized in the cytosol but not in the nuclear
fraction. Furthermore, HEK 293 cells were transiently tran-
sfected with pDsRed vector fused with STP-A11 at C-termi-
nus of DsRed protein and then examined for translocation of
p52 into the nucleus using a confocal microscope. p52 protein
was found in the nucleus of cells expressing DsRed-STP-A11,
which was confirmed by the overlap with Hoechst staining.
However, p100 protein, a precursor of p52 was present in the
cytoplasm of the cell expressing DsRed protein (Fig. 2B). This
result further confirms that the expression of STP-A11
activates NF-κB2 pathways.Fig. 2. Translocation of p52 protein into the nucleus by the expression of STP-A11. (A
were harvested and separated into cytosolic and nuclear fraction at 48 h post-tran
immunoblotting with anti-p52, anti-HA, and anti-β-tubulin antibodies. Localization
with pDsRed vector and pDsRed-STP-A11, followed by fixation and permeabilization
488-conjugated rabbit anti-mouse IgG antibody. For nucleus staining, Hoechst stain
examined with a Zeiss confocal microscope.NIK is involved in p100 processing by the expression of
STP-A11
Because a mitogen-activated protein 3-kinase, NIK, has been
known to be required for p100 processing induced by LTβ-,
B-cell-activating factor (BAFF)- and CD40-receptor-mediated
signaling (Claudio et al., 2002; Coope et al., 2002; Dejardin et al.,
2002;Mordmuller et al., 2003;Muller and Siebenlist, 2003; Xiao
et al., 2001a, 2001b), we pursued to explore whether NIK is
involved in STP-A11-mediated p52 production from p100
processing. When p52 production was compared quantitatively
between the expression of NIK and STP-A11, the expression of
NIK alone induces p52 production as similar to that of STP-A11
(Fig. 3A). Herein, we introduced NIK-KA (K429A/K430A)
mutant, with a dominant-negative function, in the presence of
STP-A11. When p52 production was quantitatively measured in
the cells expressing of NIK-KA with STP-A11 and STP-A11
alone, the expression of NIK-KA alleviated the production of p52
mediated by STP-A11 (Fig. 3B) but not drastically, indicating
that STP-A11 exerts on p100 processing to p52 through a NIK-
dependent as well as a NIK-independent mechanism.
STP-A11 induces the proteosome-mediated proteolysis of p100
to p52
To investigate whether the proteosome is involved in STP-
A-mediated p100 processing, HEK293 cells were transfected) HEK 293 cells were transfected with STP-A11 expression vector and the cells
sfection. The cell fractions were separated on 10% SDS–PAGE, followed by
of β-tubulin represents a cytosolic fraction. (B) HEK 293 cells were transfected
. The cells were stained with anti-p100 monoclonal antibody followed by Alexa-
ing solution was added for before glycerol mounting. Immunofluorescence was
Fig. 3. Partial involvement of NIK in NF-κB2 production mediated by STP-A11 (A, B) HEK 293 cells were transfected with the expression vectors encoding either
STP-A11, Myc-tagged wild type NIK or a combination of STP-A11 and NIK-KA mutant and then harvested at 48 h post-transfection. The cell lysates were separated
on 10% SDS–PAGE and immunoblotted with anti-p52, anti-HA, anti-Myc and anti-β-tubulin antibodies. The relative ratio of p52/β-tubulin protein level was
expressed after measurement of the band intensity using Multi Gauge Ver. 2.1 (Fuji Photo Film, Japan).
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thereafter treated with the proteosome inhibitor MG132 or
DMSO as a control. When p52 production was quantitatively
measured in STP-A11-expressing cells treated with MG132 or
DMSO, treatment of MG132 for 8 h almost completely blocked
the production of p52 from p100 in cells expressing STP-A11
whereas treatment of DMSO for 8 h did not (Fig. 4A). The result
suggests that STP-A11 induces the proteosome-mediated
proteolysis of p100 to p52.
Because both CD40 and BAFF receptor have been reported to
require for de novo protein synthesis in order to initiate p100
processing (Claudio et al., 2002; Coope et al., 2002; Demicco et
al., 2005), wewonder whether STP-A11-mediated p52 production
requires for protein synthesis.HEK293 cells were transfectedwith
STP-A11 expression vector and treatedwith cycloheximide for 8 h
before harvest.When p52 productionwas quantitatively measured
in STP-A11-expressing cells treated with cycloheximide or
DMSO, cycloheximide treatment inhibits p100 processing
mediated by STP-A11, compared to HEK 293 control cells treated
with DMSO (Fig. 4B). The result proposes that de novo protein
synthesis is required to induce STP-A11-mediated p100 proces-
sing efficiently as seen in CD40 and BAFF receptor signaling
(Claudio et al., 2002; Coope et al., 2002; Demicco et al., 2005).
STP-A11-mediated p52 production requires the TRAF-binding
domain but not Src-binding domain of STP-A11
To assess the relative roles of TRAF6-binding site
(10PQENDE15) and Src-binding site (115YAEV118) of theSTP-A11 oncoprotein in STP-A11-mediated p52 production,
HEK 293 cells were transfected with WT or its mutants
including E12A mutants, lack of binding to TRAF6 and
Y115A mutant, defective of binding to Src. We found that
E12A mutant, which showed a reduction of NF-κB activity,
drastically diminishes the induction of p52 production whereas
Y115A mutant which displayed a similar NF-κB activity to
that of WT, induces p52 production (Figs. 5A and B). The
result implicates that STP-A11-mediated p52 production
requires the TRAF6-binding domain but not Src-binding
domain of STP-A11.
Suppression of STP-A11-mediated p52 production with siRNA
against p52 enhances a chemotherapeutic drug-induced cell
death
To explore a significance of p52 production by STP-A11, the
expression of p52 was suppressed in HEK293 cells stably
expressing STP-A11 using its siRNA. HEK293 cells stably
expressing STP-A11 appeared to induce p52 production from
p100 processing (Fig. 6A). Next, we compared the sensitivity of
cell death induced by etoposide, a chemotherapeutic drug,
between control siRNA-treated and p52 siRNA-treated
HEK293 cells stably expressing STP-A11 or empty vector.
Either control or p52 siRNA treatment induced a similar effect
on cell survival in HEK 293 cells stably expressing empty
vector under the condition of etoposide-induced cell death.
However, STP-A11-expressing cells treated with siRNA against
p52 were more sensitive to etoposide-induced cell death than
Fig. 4. Proteosome-mediated p100 processing to p52 by the expression of STP-A11 (A, B) HEK 293 cells were transfected with STP-A11 expression vector and then
treated MG132 (20 μM) or cycloheximide (CHX; 10 μM) for 8 h before harvest. At 48 h post-transfection, the cell lysates were separated on 10% SDS–PAGE,
followed by immunoblotting with an anti-p52, anti-HA and anti-β-tubulin antibodies. The relative ratio of p52/β-tubulin protein level was expressed after
measurement of the band intensity using Multi Gauge Ver. 2.1 (Fuji Photo Film).
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HEK 293 cells stably expressing STP-A11 were cultured
without any treatment such as siRNA or etoposide, the cell
number exhibited approximately 3 times greater than the
number of the cells treated with both control siRNA and
etoposide (data not shown). We finally confirmed that reduction
of p52 expression in p52 siRNA-treated cells but not in control
siRNA-treated cells (Fig. 6C). Taken together, these results
indicate that p52 production mediated by STP-A11, an
oncoprotein of HVS, ascribes to cell survival, which would
ultimately contribute to cellular transformation.
Discussion
A growing body of evidence shows that NF-κB2 activation
promotes carcinogenesis of many tissues including mammary
gland and lymphoid cells (Demicco et al., 2005; Kim et al.,
2000; Migliazza et al., 1994; Neri et al., 1991; Neri et al.,
1996, 1995). Herein, we demonstrate that STP-A11, an
oncoprotein of HVS, additionally activates an alternative
NF-κB pathway (NF-κB2) because our previous studies have
shown that STP-A11 interacts with TRAF2 and TRAF6,
leading to a canonical activation of NF-κB. STP-C also
induces the non-canonical NF-κB pathway (NF-κB2) pathway
(data not shown). We propose that the expression of STP-A11
or STP-C activates both NF-κB pathways as the proverb says;
kill two birds with one stone.NF-κB2 signaling involved in the development of secondary
lymphoid organs such as lymph node and Peyer's patch has
been recently reported to be implicated in oncogenesis
(Franzoso et al., 1998; Futterer et al., 1998; Kang et al., 2002;
Luftig et al., 2004; Shinkura et al., 1999). p100 protein, a
precursor of p52, possesses a characteristic of a pro-apoptosis,
turning out anti-oncogenic function. However, C-terminal
truncations of p100 gene products, equivalent of NF-κB2
p52, have also been observed in a number of cases of human
cutaneous T cell lymphoma, as well as B cell lymphoma and
myelomas (Demicco et al., 2005; Kim et al., 2000; Migliazza et
al., 1994; Neri et al., 1991, 1996, 1995). In a transgenic mice
model, RelB:p52 NF-κB2 complex accelerates carcinogenesis
of the mammary gland (Wang et al., 2002). Therefore, we
suggest that the expression of NF-κB2 p52 protein in clinical
tissues would be associated with tumorigenesis. Furthermore,
the results which show that STP-A11 induces p52 production
from p100 processing (Figs. 1,2 and 5) might closely correlate
with our suggestion. The result shown that suppression of p52
using its siRNA enhances a susceptibility of drug-induced cell
death in STP-A11-expressing cells (Fig. 6) supports our
suggestion. Additionally, blockage of p52 in STP-C-expressing
cells enhances the drug-induced cell death as similar to STP-
A11 (data not shown).
It is interesting that NF-κB is a common target for oncogenic
viral proteins including Tax protein of human T lymphocytic
leukemia virus (HTLV)-1, Core protein of hepatitis C virus and
Fig. 5. Requirement of TRAF6-binding site for STP-A11-mediated p100
processing but not Src-binding site. (A) HEK 293 cells were transfected with the
expression vectors encoding STP-A11 or its mutants including E12A mutant
and Y115A mutant and harvested at 48 h post-transfection. The cell lysates were
separated on 10% SDS–PAGE and immunoblotted with anti-p52, anti-HA and
anti-β-tubulin antibodies. (B) HEK 293 cells were transfected with NF-κB
luciferase reporter vector and expression vectors encoding WT or its mutants
E12A, or Y115A of STP-A11. At 48 h post-transfection, cells were harvested
and luciferase activity was measured. Transfection efficiency was normalized
with β-galactosidase reporter vector pGK-β-gal.
Fig. 6. Enhancement of a drug-induced cell death by suppression of STP-A11-
mediated p52 production using siRNA against p52. (A) HEK 293 cells stably
expressing STP-A11 were cultured and harvested for cell lysates. The cell
lysates were then separated on 10% SDS–PAGE and immunoblotted with anti-
p52, anti-HA and anti-β-tubulin antibodies. (B) HEK293 cells stably expressing
STP-A11 or an empty vector grown in 6-well plates were transfected with either
control siRNA (20 μM) or p52 siRNA (20 μM). At 24 h post-transfection,
etoposide was added into the cells and the cells were incubated for 48 h and
counted using trypan blue. (C) Suppression of p52 in HEK 293 cells stably
expressing STP-A11 treated with p52 siRNA but not with control siRNA was
confirmed by immunoblotting with anti-p52 antibody.
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Yin et al., 1998; Yoshida et al., 2001). In particular, Tax of
HTLV-1 and LMP-1 of EBV have been reported to activate NF-
κB2 pathways as well as a canonical pathway of NF-κB. Of
interest, NF-κB2 activation mediated by LMP-1 of EBV is
critically dependent on NIK and IKK1 but independent on IKK-
γ, whereas NF-κB2 induction by Tax protein of HTLV-1 relies
on IKK-γ but not on NIK (Atkinson et al., 2003; Eliopoulos et
al., 2003; Luftig et al., 2004; Xiao et al., 2001a, 2001b). Our
observation (Fig. 3) that over-expression of NIK-KA (K429A/
K430A) mutant, a potent NIK inhibitor, partially inhibits STP-
A11-mediated p100 processing to p52 suggests that NIK
cooperates with STP-A11 for p100 processing to p52, but that
NIK is not absolutely required for NF-κB2 activation by STP-
A11. We will pursue to study an exact role of NIK in STP-A11-
mediated NF-κB2 activation in the future experiment to
differentiate a role of NIK in Tax- or LMP-1-mediated NF-
κB2 activation. Nevertheless, in spite of the expression of
different viral proteins such as Tax, LMP-1 and STP-A11, p100
processing commonly takes place in 26S proteosome.
STP-A11 has distinct domains for binding to TRAF2 at
60PVQES64 and TRAF6 at 10PQENDE15, and Src at
115YAEV118. Src-binding domain involved in a minor role in
NF-κB activation is dispensable for p100 processing, but TRAF
6 domain as well as TRAF2 domain (unpublished data) play an
important role in p100 processing to p52. LMP-1 of EBV, a
distinct open reading frame from STP-A11 exhibits that TRAF-
binding site is required for LMP-1-induced p100 processing butnot the death-domain site (Atkinson et al., 2003; Eliopoulos et
al., 2003; Luftig et al., 2004). CD40 also depends on its TRAF2,
3, 5-binding sites for p100 processing (Coope et al., 2002).
Furthermore, introduction of IκB-α(S32A/S36A) mutant, a
dominant-negative mutant of canonical NF-κB pathway, failed
to block the activation of NF-κB2 pathway mediated by LMP-1
(Atkinson et al., 2003) and STP-A11 (unpublished data),
suggesting that NF-κB2 activation does not require NF-κB
activity. These lines of evidence are supported by the report that
RelB:p52 complexes do not interact well with IκB-α, and thus
largely free to migrate.
Because numerous lines of evidence have shown that
activation of NF-κB is implicated in anti-apoptosis and cell
proliferation (Ghosh and Karin, 2002; Karin and Lin, 2002;
Zhang and Ghosh, 2001), both pathways of NF-κB enhanced by
STP-A11 would contribute to survival of HVS-infected cells,
leading to an acquisition of enough time to facilitate HVS
propagation in the cells. This could be a strategy of viral survival
during early phase of infection. Furthermore, we suggest that
HVS has been evolved to develop a safe double lock system,
which would help evade a risk from a blockage of any NF-κB
pathway. Clinically, as an elevated NF-κB expression and
inflammatory cytokines have been very frequently found in
tumor tissues from various sources (Feinman et al., 1999;
Griffin, 2001; Palayoor et al., 1999), it has been suggested that
activated inflammation is a significant risk factor of oncogenesis
(Aggarwal, 2004). Accordingly, we speculate that the exposure
43I.-R. Cho et al. / Virology 359 (2007) 37–45of HVS-infected cells with chronic inflammatory microenvi-
ronment and chronic activation due to activation of NF-κB,
ultimately ascribes to cellular transformation.
Materials and methods
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells and Jurkat T
lymphocytes were cultured in Dulbecco's modified Eagle's
medium (DMEM) and RPMI-1640 supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin and streptomycin,
respectively. HEK 293 cells were plated at 1×106 cells per 100-
mm-diameter plate 24 h before transfection and the cells were
then transfected with 8 to 15 μg of DNA using calcium
phosphate precipitation method (Clontech, Palo Alto, CA).
Jurkat T cells were electroporated with 10 μg of DNA at 260 μF,
960 V and then cultured for 48 h for the detection of p52
production.
Plasmid construction and antibodies
The following vectors have been described elsewhere;pEF-
HA-STP-A11, pEF-HA-STPA11-Y115A (Chung et al., 2004),
pEF-HA-STP-A11-E12A, pCMV-Myc-NIK, pCMV-Myc-NIK-
KA (K429A/K430A) (Yin et al., 1998). To construct a stable
cells expressing WTor its mutants of STP-A11, STP-A11 genes
were subcloned into pEF-IRES-puromycin vector. To examine
translocation of p52 protein using a confocal microscope, the
STP-A11 gene was amplified by PCR and inserted in frame into
the pDsRed vector at the C-terminus of a variant Discosoma sp.
red fluorescence protein (Clontech). To block completely NF-
κB pathway, pUSE-IκB (S32A/S36A) vector purchased at
Upstate Biotechnology, Inc. (Charlottesville, VA) was used. For
antibodies, anti-p100 monoclonal antibody, which can cross-
react to p52 protein, was purchased at Upstate Biotech. Anti-
β-tubulin, anti-HA, anti-Myc and anti-RelB antibodies were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Immunoprecipitation and immunoblotting
Cells were harvested and lysed with lysis buffer (0.15 M
NaCl, 1% Nonidet P-40, 50 mM Tris [pH 7.5]) containing
0.1 mMNa2VO3, 1 mMNaF and protease inhibitors (Sigma, St.
Louis, MO). For immunoblotting, proteins from whole cell
lysate were resolved by 10% or 12% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) and then
transferred to nitrocellulose membranes. Primary antibodies
were used at 1:1,000 or 1:2,000 dilutions, and secondary
antibodies were used at 1:2,000 dilution in 6% nonfat dry milk.
After final washing, nitrocellulose membranes were exposed for
an enhanced chemiluminescence assay.
NF-κB reporter assay
HEK 293 cells were transfected with wild-type (WT) or its
mutant STP-A11 vector together with NF-κB-luciferase reportervector by the calcium phosphate precipitation method. To
normalize transfection efficiency, the pGK-β-gal vector, which
expresses β-galactosidase from a phosphoglucokinase promot-
er, was included in the transfection mixture. At 48 h post-
transfection, cells were washed with cold phosphate-buffered
saline (PBS) and lysed in lysis solution (25 mM Tris [pH 7.8],
2 mM EDTA, 2 mM DTT, 10% glycerol and 1% Triton X-100).
Luciferase activity was measured with a luminometer by using a
luciferase assay kit (Promega, Madison, WI).
Cell fractionation
As described elsewhere (Habelhah et al., 2004), cells
cultured in 100-mm plate were washed and harvested with
ice-cold PBS and cell pellets were lysed with 800 μl of TTN
buffer (20 mM Tris–HCl [pH 7.4], 0.05% Triton-X100,
150 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol,
0.5 mM PMSF and 1× cocktail protease inhibitor) on ice for
20 min, followed by centrifugation at 10,000×g for 15 min. The
supernatant was taken as a cytosol fraction and the pellets were
washed with 500 μl of TTN buffer and the remaining pellets
were subsequently solubilized in 800 μl of RIPA buffer (50 mM
Tris–HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM DTT,
1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 10% glycerol,
0.5 mM PMSF and 1× cocktail protease inhibitor) on ice for
30 min. Extracts were centrifuged at 12,000×g for 15 min and
the supernatant was taken as the nuclear extraction fraction.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 30 min,
permeabilized with cold acetone for 15 min, blocked with
10% goat serum in PBS for 30 min and reacted with 1:500 to
1:2,000 dilutions of primary antibody in PBS for 30 min at
room temperature. After incubation, cells were washed
extensively with PBS, incubated with a 1:500-diluted Alexa-
488-conjugated, anti-mouse antibody (Molecular Probes,
Eugene, OR) in PBS for 30 min at room temperature and
washed three times with PBS. For the nucleus staining,
Hoechst 33258 staining solution (4 μg/ml; Sigma, St. Louis,
MO) was added for 30 min. The stained cells were mounted
with PBS containing 10% glycerol and photographed with a
confocal microscope (LSM510, Zeiss, Germany).
siRNA transfection
HEK 293 cells stably expressing STP-A11 were plated at
equal densities in 6-well plate (2×105 cells/well) and were
transfected with siRNAs against NF-κB2 or a nonspecific
control at 24 h after splitting using siPORT Amine (Ambion,
Austin, TX) as described by the manufacturer's instruction.
Sequences usedwere as follows. For the control, si RNA control;
5′-CCU ACG CCA CCA AUU UCG U-3′ as sense, 5′-ACG
AAAUUGGUGGCGUAGG-3′ as antisense were synthesized
and for NF-κB2, two siRNAs were used: #1 5′-GACAAGGAA
GAGGUGCAGCTT-3′ as sense and 5′-GCUGCACCUCUU
CCU UGU CTT-3′ as antisense and #2 5′-GCC CUG AGU
44 I.-R. Cho et al. / Virology 359 (2007) 37–45GCC UGA AUC U-3′ as sense and 5′-AGA UCC AGG CAC
UCA GGG CTT-3′ as antisense. At 24 h post-transfection, cells
were treated with final concentrations of 10–20 μMof etoposide
(Sigma) for 48 h and counted using trypan blue.
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